cardiovascular outcomes

Individual GLP-1 Receptor Agonists and SGLT2 Inhibitors Show Largely Comparable Cardiovascular Protection in Type 2 Diabetes

By MedXY 06/10/2026

A multinational real-world study found broadly similar cardiovascular effectiveness across individual GLP-1 receptor agonists and SGLT2 inhibitors in metformin-treated type 2 diabetes, including among patients with established cardiovascular disease.

Cardiology news

Exploring the Impact of Body Mass Index on Heart Failure Outcomes: Insights from Mendelian Randomization

By MedXY 06/10/2026

This study leverages Mendelian randomization to demonstrate that genetically elevated BMI is associated with increased mortality and adverse cardiovascular outcomes in heart failure, irrespective of ejection fraction status, underscoring potential benefits of weight management.

Cardiology news

Body Mass Index, Clinical Outcomes, and Mortality in Heart Failure: A Mendelian Randomization Study

By MedXY 06/10/2026

This study uses Mendelian randomization to show that higher genetically predicted BMI is associated with increased all-cause mortality and cardiovascular events in heart failure patients, regardless of ejection fraction status.

Cardiology news Respiratory

Cardiovascular Benefit of CPAP May Be Greater in High-Risk Obstructive Sleep Apnoea

By MedXY 05/15/2026

This pooled analysis found that CPAP may lower cardiovascular event risk mainly in patients with high-risk obstructive sleep apnoea, especially those with stronger heart-rate surges or greater oxygen deprivation during sleep.

Cardiology news

Rationale and Design of CARDIO-TTRansform: A Phase 3 Trial of Eplontersen for Transthyretin Amyloid Cardiomyopathy

By MedXY 05/10/2026

CARDIO-TTRansform is a global Phase 3 trial evaluating eplontersen's efficacy and safety in reducing cardiovascular events in transthyretin amyloid cardiomyopathy patients receiving standard care, including TTR stabilizers. With 1,432 participants, it aims to establish a new treatment paradigm.

Cardiology Diabetes & Endocrinology news

No Clear Winner: Real-World Evidence Shows GLP-1RAs and SGLT2 Inhibitors Deliver Comparable Cardiovascular Benefits in Type 2 Diabetes

By MedXY 04/18/2026

A large-scale multinational study of over 1.2 million patients reveals that individual GLP-1 receptor agonists and SGLT2 inhibitors offer broadly similar cardiovascular protection in type 2 diabetes, challenging assumptions about meaningful differences between agents.

Clinical Updates Neurology news Rehabilitation Medicine

Integrated Strategies for Stroke Prevention and Management: From Evidence-Based Dietary Patterns to Systemic Adherence

By MedXY 04/08/2026

This review synthesizes recent evidence on the neuroprotective effects of healthy dietary patterns (Mediterranean, MIND), the synergistic impact of lifestyle and pharmacotherapy (GLP-1), and systemic advances in acute stroke care and secondary prevention.

Clinical Updates news

Evolution and Future Frontiers of PCSK9 Inhibition: From Genetic Discovery to Genomic Medicine

By MedXY 03/25/2026

This review synthesizes the trajectory of PCSK9 inhibitors, from pivotal monoclonal antibody trials to emerging RNA interference and gene-editing technologies, emphasizing their role in achieving ultra-low LDL-C levels and reducing major adverse cardiovascular events.

Cardiology Diabetes & Endocrinology news

Tirzepatide Outperforms Dulaglutide in Cardiovascular Risk Reduction: Insights from Real-World Target-Trial Emulations

By MedXY 03/11/2026

A large-scale target-trial emulation study reveals that tirzepatide significantly reduces the risk of major adverse cardiovascular events (MACE) and all-cause mortality compared to dulaglutide in patients with type 2 diabetes and ASCVD, while performing similarly to semaglutide.

Diabetes & Endocrinology Nephrology news

GLP-1 Receptor Agonists Significantly Reduce MACE Risk Across the CKD Spectrum, Yet Prescription Rates Remain Suboptimal

By MedXY 02/03/2026

Recent data highlights that GLP-1 receptor agonists (GLP1-RAs) reduce cardiovascular risk in patients with chronic kidney disease (CKD), yet real-world prescription rates remain alarmingly low despite these proven benefits across various stages of renal impairment.

Diabetes & Endocrinology Gastroenterology news

SGLT2 Inhibitors Emerge as Superior Choice for Cardiovascular Protection in Patients with T2DM and MASLD

By MedXY 01/07/2026

A nationwide target trial emulation reveals that SGLT2 inhibitors significantly reduce major adverse cardiovascular events and mortality compared to other oral antidiabetics in patients with concurrent T2DM and MASLD, with benefits partially mediated by liver disease regression.

Cardiology Diabetes & Endocrinology news

Semaglutide Extends Survival in Non-Overweight Type 2 Diabetes Patients: New Evidence Challenges BMI-Centric Treatment Models

By MedXY 01/04/2026

A large-scale retrospective study demonstrates that semaglutide reduces all-cause mortality by 46% in non-overweight patients with Type 2 diabetes compared to DPP-4 inhibitors, highlighting cardioprotective benefits independent of weight reduction.

AI Cardiology news

AI-Based OCT Analysis Outperforms Human Experts in Predicting Outcomes from Non-Culprit Lesions: Insights from the PECTUS-AI Study

By MedXY 01/03/2026

The PECTUS-AI study demonstrates that AI-based identification of thin-cap fibroatheromas using OCT provides superior prognostic value for cardiovascular events compared to manual analysis, particularly when assessing the entire imaged coronary segment, offering a standardized approach to identifying high-risk patients.

Cardiology General Surgery news

Endoscopic Radial Artery Harvesting Superior to Open Technique for Hand Function and Neurologic Protection in CABG

By MedXY 12/31/2025

A randomized trial reveals that endoscopic radial artery harvesting for CABG leads to better patient-reported hand function and significantly fewer neurologic deficits compared to the traditional open technique, potentially redefining the standard of care for conduit acquisition.

Cardiology Clinical Updates Neurology news Respiratory

Comparative Effectiveness of High-Dose versus Standard-Dose Influenza Vaccines in Chronic Kidney Disease and Cardiovascular Disease: Integrated Insights from the DANFLU-2 Trial

By MedXY 12/25/2025

The DANFLU-2 trial demonstrates that high-dose influenza vaccine provides superior protection against influenza-related hospitalizations in chronic kidney disease and reduces cardiorespiratory hospitalizations in older adults irrespective of cardiovascular disease status.

Cardiology Clinical Updates Diabetes & Endocrinology news

Diabetes, Obesity, and Early Rhythm Control in Atrial Fibrillation: Insights from the EAST-AFNET 4 Trial

By MedXY 12/22/2025

This analysis of the EAST-AFNET 4 trial highlights that early rhythm control therapy's cardiovascular benefits and safety are consistent regardless of diabetes or obesity status in atrial fibrillation patients.

Cardiology Diabetes & Endocrinology news

Tirzepatide Achieves Cardiovascular Noninferiority Against Dulaglutide: A Milestone in Dual Incretin Therapy

By MedXY 12/18/2025

The SURPASS-CVOT trial confirms that tirzepatide is noninferior to dulaglutide for cardiovascular safety in high-risk type 2 diabetes patients. While superiority was not statistically reached, the study solidifies the cardiovascular profile of dual GIP/GLP-1 agonism compared to established standards of care.

Cardiology Diabetes & Endocrinology news

Normalising Renin After Medical Therapy for Primary Aldosteronism May Lower Cardiovascular Risk — But RCTs Are Needed

By MedXY 11/30/2025

A 2025 systematic review and meta-analysis found that patients with primary aldosteronism whose renin rose after mineralocorticoid receptor antagonist therapy had substantially lower cardiovascular event rates and possibly lower mortality, suggesting renin normalisation as a therapeutic target pending prospective confirmation.

Cardiology Nephrology news

SGLT2 Inhibitors Remain Protective Even After Severe eGFR Decline: Pooled Trial Analysis Across Cardio‑Renal‑Metabolic Populations

By MedXY 11/28/2025

A pooled analysis of five randomized trials (n=26,946) found that severe eGFR deterioration (<25 and <20 ml/min/1.73 m2) increased cardiovascular risk nearly twofold, but SGLT2 inhibitors reduced that risk and retained benefit regardless of subsequent severe kidney decline.

Cardiology Diabetes & Endocrinology news

Semaglutide’s Cardioprotection in SELECT: Beyond Weight Loss — Waist Reduction Explains a Third of the Benefit

By MedXY 11/11/2025

In the SELECT trial, weekly semaglutide 2.4 mg reduced major adverse cardiovascular events in people with overweight/obesity without diabetes. Benefits were largely independent of baseline adiposity and weight loss; waist circumference reduction explained ~33% of the observed effect.